The latest update is out from Xeris Pharmaceuticals ( (XERS) ).
On February 24, 2025, Xeris Biopharma announced the retirement of Ken Johnson as Senior Vice President, Global Development and Medical Affairs, effective April 1, 2025, and the appointment of Dr. Anh Nguyen as Chief Medical Officer, effective immediately. Dr. Nguyen, who brings extensive clinical and leadership experience, will lead the strategic direction for Xeris’ medical and regulatory functions, coinciding with the company’s Phase 3 development of XP-8121 and efforts to expand its commercial portfolio. This leadership transition is expected to ensure continuity and drive future growth, with Mr. Johnson assisting in the transition process.
More about Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company focused on improving patient lives by developing and commercializing innovative products across a range of therapies. The company offers three commercially available products: Recorlev® for endogenous Cushing’s syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. Xeris is also advancing its pipeline with XP-8121, a Phase 3-ready treatment for hypothyroidism, and other early-stage programs using its XeriSol® and XeriJect® technology platforms.
YTD Price Performance: 8.38%
Average Trading Volume: 1,652,406
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $559.1M
For detailed information about XERS stock, go to TipRanks’ Stock Analysis page.